Today’s podcast features an interview with Glenn Bubley, MD, director of the Division of Genitourinary Medical Oncology at the Beth Israel Medical Center and associate professor of medicine at Harvard Medical School. He is the 2009 recipient of the Jack Colbert Memorial Award.

On this podcast he discusses the good news about new treatments for metastatic and non-metastatic prostate cancer. Important clinical trials have been performed that have shown that earlier treatment of metastatic disease with combinations of existing agents have provided a major improvement in overall and cancer specific survival. This includes combinations of hormonal agents like Lupron with Abiraterone or Lupron with the chemotherapeutic agent Docetaxel.

At the May 10, 2019, Prostate Cancer Symposium his session is “Newer Therapeutic Strategies for Advanced Prostate Cancer.”